MX2020006594A - Inhibidores de exo-azaespiro de la interaccion menina-mll. - Google Patents

Inhibidores de exo-azaespiro de la interaccion menina-mll.

Info

Publication number
MX2020006594A
MX2020006594A MX2020006594A MX2020006594A MX2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A
Authority
MX
Mexico
Prior art keywords
menin
inhibitors
exo
aza spiro
mll interaction
Prior art date
Application number
MX2020006594A
Other languages
English (en)
Inventor
Patrick René Angibaud
Virginie Sophie Poncelet
Olivier Alexis Georges Querolle
Wei Cai
Vineet Pande
Daniel Jason Krosky
Aaron Nathaniel Patrick
James Patrick Edwards
Xuedong Dai
Liqiang Fu
Linglong Kong
Yingtao Liu
Zhao - Kui WAN
Geb Herkert Barbara Morschhäuser
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020006594A publication Critical patent/MX2020006594A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para terapia y/o profilaxis en un mamífero, composición farmacéutica que comprende dichos compuestos, y su uso como inhibidores de la interacción proteína/proteína menina/MLL, útiles para tratar enfermedades tales como cáncer, síndrome mielodisplásico (MDS) y diabetes.
MX2020006594A 2017-12-20 2018-12-19 Inhibidores de exo-azaespiro de la interaccion menina-mll. MX2020006594A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017117536 2017-12-20
CN2018091521 2018-06-15
PCT/CN2018/121960 WO2019120209A1 (en) 2017-12-20 2018-12-19 Exo-aza spiro inhibitors of menin-mll interaction

Publications (1)

Publication Number Publication Date
MX2020006594A true MX2020006594A (es) 2020-09-09

Family

ID=66993097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006594A MX2020006594A (es) 2017-12-20 2018-12-19 Inhibidores de exo-azaespiro de la interaccion menina-mll.

Country Status (12)

Country Link
US (1) US20230039917A1 (es)
EP (1) EP3728260A4 (es)
JP (1) JP7307729B2 (es)
KR (1) KR20200101389A (es)
CN (1) CN111601807B (es)
AU (1) AU2018389145B2 (es)
BR (1) BR112020012461A2 (es)
CA (1) CA3083624A1 (es)
IL (1) IL275457A (es)
MA (1) MA51337A (es)
MX (1) MX2020006594A (es)
WO (1) WO2019120209A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805215A1 (en) 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
CN110950818B (zh) * 2019-12-18 2021-12-28 浙江海翔药业股份有限公司 顺式-2,6-二甲基吗啉的纯化方法
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
MX2022012471A (es) 2020-04-07 2022-11-30 Syndax Pharmaceuticals Inc Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
TW202302565A (zh) * 2021-02-19 2023-01-16 英商卡爾維斯塔製藥有限公司 酶抑制劑
EP4334320A1 (en) * 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
MX2023013174A (es) 2021-05-08 2023-11-30 Janssen Pharmaceutica Nv Derivados espiro sustituidos.
TW202311262A (zh) 2021-05-14 2023-03-16 美商錫達斯醫藥股份有限公司 Menin-mll交互作用之抑制劑
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473054B1 (en) 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
CN103781780B (zh) 2011-07-28 2015-11-25 赛尔佐姆有限公司 作为jak抑制剂的杂环基嘧啶类似物
KR20150130389A (ko) * 2013-03-13 2015-11-23 더 리젠츠 오브 더 유니버시티 오브 미시간 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
MA40957A (fr) 2014-10-09 2017-09-19 Biomarin Pharm Inc Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
WO2017207387A1 (en) * 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
EP3805215A1 (en) * 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
MA46228A (fr) 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
CA3033239A1 (en) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
US10899758B2 (en) 2016-09-16 2021-01-26 Vitae Pharmaceuticals, Llc Inhibitors of the menin-MLL interaction
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
US11396517B1 (en) * 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction

Also Published As

Publication number Publication date
KR20200101389A (ko) 2020-08-27
MA51337A (fr) 2020-10-28
RU2020123548A3 (es) 2022-02-17
WO2019120209A1 (en) 2019-06-27
JP7307729B2 (ja) 2023-07-12
CN111601807A (zh) 2020-08-28
EP3728260A1 (en) 2020-10-28
AU2018389145A1 (en) 2020-05-21
IL275457A (en) 2020-08-31
CN111601807B (zh) 2023-03-31
EP3728260A4 (en) 2021-08-11
CA3083624A1 (en) 2019-06-27
JP2021506882A (ja) 2021-02-22
RU2020123548A (ru) 2022-01-20
BR112020012461A2 (pt) 2020-11-24
AU2018389145B2 (en) 2023-02-02
US20230039917A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX389598B (es) Inhibidores bicíclicos condensados de la interacción de menina-mll.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
MX392051B (es) Inhibidores espirobiciclicos de la interaccion de menina-mll
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
MX383213B (es) Inhibidores de tirosina-cinasas
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
NZ719905A (en) Bicyclic heterocycle compounds and their uses in therapy
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201991448A1 (ru) Азепановые ингибиторы взаимодействия менин-mll
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
JOP20210128A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
EA201790349A1 (ru) Производные 6-алкинил-пиридина в качестве миметиков белка smac
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX391405B (es) Inhibidores de azepano de la interacción menina-mll.